Pricing Log in Create free account
Sunday 18 October 2026 Export IPSC’s income statement to Excel — free account

Century Therapeutics, Inc.

IPSC Healthcare Biotechnology

Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.37 0.13 −8.67%
Market cap
$271.6M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
4/9
Altman Z
−3.39
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10
Total sells 0.09
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 2 — — — — — — — — — —
Sell 3 2 — 1 4 — 1 4 — 1 4 —
Insider Ownership 40.24%

Capital & Financial Ratios $m

Market Cap 271.61
Revenue 114.90
Net Income (109.79)
Free Cash Flow (88.03)
Net Debt (119.71)
Current Ratio 8.28 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (4.46) (negative: loss-making)
P/S ratio 2.45
P/B ratio 1.21
Past 5Y EPS Growth —
This Y EPS Growth (274.29%) (below 0%: weak)
Next Y EPS Growth 14.44%
Next Y revenue growth 0.03%
Next 5Y EPS Growth 29.46% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of −1.0×; over the ten years it ranged from −37.4× in 2024 to 36.6× in 2024.
P/S against its own 10 years 26.71%
10-year low 10-year high
P/B against its own 10 years 64.69%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 173 189 117 120
Receivables — — — —
Inventory — — — —
Other — — — —
177 194 121 125
2023 2024 2025 Q'26
Payables 3 3 5 5
ST’ Debt 1 0 0 —
Other — — 4 —
18 130 20 15

Compound Annual Growth %

10y 5y 3y
Sales — — 175.88%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 16.73% (19.33%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 109 — — — 109
’24 1 1 1 4 7
’23 2 0 0 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (25) (20) — — —
’25 (35) (28) (26) (16) (104)
’24 (30) (27) (28) (24) (110)
’23 (29) (19) (14) (26) (88)
’22 87 (26) (24) (23) 14
’21 (22) (18) (24) (24) (89)
’20 (7) (19) (9) (13) (41)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (20) — — —
’25 (35) (28) (26) (16) (105)
’24 (31) (28) (28) (24) (110)
’23 (34) (24) (17) (27) (102)
’22 83 (36) (34) (29) (17)
’21 (24) (29) (40) (41) (134)
’20 (7) (22) (14) (15) (51)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.11) (0.17) — — —
’25 0.89 (0.38) (0.40) (0.25) (0.11)
’24 (0.45) (0.38) (0.37) (0.43) (1.61)
’23 (0.53) (0.56) (0.55) (0.65) (2.30)
’22 (0.66) (0.54) (0.53) (0.55) (2.27)
’21 (2.39) (1.93) (0.48) (0.24) (2.96)
’20 — (2.04) (1.75) — (7.16)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 13.08 4.69 1.28 0.95 0.34

Analyst estimates 2026–2028

Powerpack
High — — — — — 32.90 16.83 5.34 5.51 1.19
People
People Employees — — — — 107 188 184 165 150 78
Revenue/emp, $m — — — — 0.00 0.00 0.03 0.01 0.04 1.40
Income, $m
Income, $m Revenue — — — — — — 5 2 7 109
Gross margin, % — — — 0.00 0.00 0.00 100.00 100.00 100.00 100.00
EBT — — — (245) (54) (96) (131) (135) (125) (10)
EBT margin, % — — — 0.00 0.00 0.00 (2,516.66) (6,030.96) (1,893.70) (8.84)
Net income — 0 — (245) (54) (96) (131) (137) (127) (10)
Depreciation — — — 0 1 4 9 9 8 11
Per share, $
Per share, $ Revenue — — — 0.00 0.00 0.00 0.09 0.04 0.08 1.26
Earnings — — — (4.46) (7.16) (2.96) (2.27) (2.30) (1.61) (0.11)
Cash flow — — — (0.29) (5.52) (2.75) 0.24 (1.49) (1.40) (1.20)
Capex — — — 0.00 (1.31) (1.39) (0.53) (0.23) 0.00 (0.01)
Free cash flow — — — (0.29) (6.83) (4.14) (0.29) (1.72) (1.40) (1.21)
Book value — — — 2.88 9.80 12.23 5.24 3.11 2.05 1.84
Shares, m — — — 55 7 32 58 59 79 87
Valuation, ×
Valuation, × P/E — — — — — — 0.00 0.00 0.00 0.00
P/S — — — — — — 55.21 96.60 12.06 0.75
P/B — — — — — — 0.95 1.17 0.49 0.54
EV/Sales — — — — — — (3.20) 19.60 (16.66) (0.27)
EV/FCF — — — — — — 1.00 (0.43) 1.00 0.29
Cash, $m
Cash, $m Operating cash flow — — — (16) (41) (89) 14 (88) (110) (104)
Capex — — — (2) (10) (45) (31) (14) 0 (1)
Free cash flow — — — (16) (51) (134) (17) (102) (110) (105)
Balance, $m
Balance, $m Working capital — — — 81 67 212 290 159 64 101
Total debt — — — — 10 13 12 1 0 0
Net debt — — — (82) (66) (210) (304) (172) (189) (117)
Shareholders’ equity — — — 158 73 396 303 185 161 159
Returns, %
Returns, % ROA — — — (304.26) (40.03) (35.22) (28.34) (32.26) (35.46) (3.32)
ROIC — — — 0.00 (450.83) (31.83) 0.00 (723.93) 0.00 (25.79)
ROE — — — (186.03) 83.53 (66.13) (37.46) (56.07) (73.14) (5.98)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Century Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FULC Fulcrum Therapeutics, Inc. $280.0M — (loss-making) — (loss-making) +27,018.64% (above 0%: growing) n/m −13.05% (below 0%: shrinking) 100.00% 0.00% Compare
OCGN Ocugen, Inc. $275.9M — (loss-making) — (loss-making) +8.38% (above 0%: growing) n/m −13.42% (below 0%: shrinking) 100.00% (1,105.11%) Compare
NAUT Nautilus Biotechnology, Inc. $274.9M — (loss-making) — — n/m −3.16% (below 0%: shrinking) 92.11% (8,296.32%) Compare
IPSC Century Therapeutics, Inc. $271.6M — (loss-making) — (loss-making) +12,667.72% (above 0%: growing) n/m +26.66% (above 0%: growing) 100.00% 0.00%
EYPT EyePoint, Inc. $270.7M — (loss-making) — (loss-making) −90.49% (below 0%: shrinking) n/m +0.41% (above 0%: growing) 100.00% (19,207.10%) Compare
PALI Palisade Bio, Inc. $268.4M 2.2× — (loss-making) +19,900.00% (above 0%: growing) n/m −318.44% (below 0%: shrinking) 100.00% (2,339.60%) Compare
ABEO Abeona Therapeutics Inc. $265.9M — (loss-making) — (loss-making) +225.14% (above 0%: growing) n/m +17.11% (above 0%: growing) 63.30% (119.97%) Compare
PRLD Prelude Therapeutics Incorporated $265.0M — (loss-making) — (loss-making) +42.60% (above 0%: growing) n/m +40.32% (above 0%: growing) 100.00% (270.93%) Compare
CABA Cabaletta Bio, Inc. $262.8M — (loss-making) — — n/m −35.72% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $269.5M — — +133.87% — −8.11% 100.00% (688.02%)

All 614 Biotechnology stocks →

Century Therapeutics, Inc. (IPSC) key facts

  • Strength: Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024.
  • Century Therapeutics, Inc. (IPSC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IPSC traded at $1.37, a market capitalization of $271.6 million.
  • Return on equity was −5.98% and debt-to-equity 0.00.
  • Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −3.39 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Century Therapeutics, Inc. (IPSC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IPSC · Data as of Mar 31, 2025 · For information only; not investment advice. · © 2026 stockrow.com